:: 
FP7-Health-2009 BIOTECH, HUMAN HEALTH HEALTHCARE one-stage <03Dec08 + two stages <22Apr09
Deadlines: 03 December 2008 at 17:00:00 (Brussels local time) 22 April 2009 at 17:00:00 (Brussels local time) - Second deadline (for 2-stage procedure indicative) OJ Reference: OJ C226 of 03 September 2008 Specific Programme(s): Cooperation Theme: Health
Call identifier: FP7-HEALTH-2009-single-stage
Proposal submission and evaluation: Single-stage procedure
Date of publication: 3 September 2008.
Deadline: 3 December 2008 at 17.00.00 (Brussels local time).
Indicative budget: EUR 476 million from the 2009 budget
The budget for this call is indicative. The final budget awarded to this call, following the evaluation of proposals, may vary: by up to 10% of the total value of the call; and the repartition of sub-budgets awarded within this call, following the evaluation of proposals, may vary by up to 10% of the total value of the call.
ACTIVITY/AREA Indicative budget (EUR million)
1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH 120
1.2 DETECTION, DIAGNOSIS AND MONITORING
1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS
2. TRANSLATING RESEARCH FOR HUMAN HEALTH 41
2.2 RESEARCH ON THE BRAIN AND
2.2.1. Brain and brain-related diseases
2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH 75
2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES 95
3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS 64
3.1. TRANSLATING THE RESULTS OF CLINICAL RESEARCH OUTCOME INTO CLINICAL
PRACTICE INCLUDING BETTER USE OF MEDICINES, AND APPROPRIATE USE OF BEHAVIOURAL AND ORGANISATIONAL INTERVENTIONS AND NEW HEALTH THERAPIES AND TECHNOLOGIES
3.2. QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS
3.3. ENHANCED HEALTH PROMOTION AND DISEASE PREVENTION
4.1. COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME 3
4.2. RESPONDING TO EU POLICY NEEDS 33
4.3. SPECIFIC INTERNATIONAL COOPERATION ACTIONS (SICA)
4. OTHER ACTIONS ACROSS THE
4.3.1. Neglected infectious diseases 27
4.3.2. International Public Health and Health Systems 12
4.3.3. Coordinated topics with Russia 6
Topics called:
Activity/Area Topics called Funding Schemes
1.BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH
1.2 DETECTION, DIAGNOSIS AND MONITORING
1.2 HEALTH-2009-1.2-1: Development of tools for sensitive and
specific in vitro detection of proteins and their interactions for
diagnostic, prognostics and monitoring purposes.
Collaborative Project (Small or medium-scale focused research project)
1.2 HEALTH-2009-1.2-2: Design of methods suited to identify epigenetic factors and their use in the genetic diagnosis of
relevant disorders.
Collaborative Project (Small or medium-scale focused research project)
1.2 HEALTH-2009-1.2-3: Novel MR-compatible PET detectors for simultaneous PET/MRI imaging.
Collaborative Project (Largescale integrating project)
1.2 HEALTH-2009-1.2-4: Novel imaging systems for in vivo
monitoring and quality control during tumour ion beam therapy.
Collaborative Project (Small or medium-scale focused research project)
1.2 HEALTH-2009-1.2-5: Activatable or smart in vivo imaging agents reporting on physico-chemical or molecular changes
relevant to the diagnosis and/or monitoring of diseases
Collaborative Project (Small or medium-scale focused research project)
1.2 HEALTH-2009-1.2-6: Evaluation of the potential health impact of diagnostic imaging agents doses.
Coordination and Support Action (Supporting Action)
1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES
1.3 HEALTH-2009-1.3-1: New initiatives towards the implementation of the Replace, Reduce and Refine strategy.
Coordination and Support Action (Coordinating Action)
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS
1.4 HEALTH-2009-1.4-1: Cell therapy for tissue and organs. Collaborative Project (Largescale integrating project)
1.4 HEALTH-2009-1.4-2: Regeneration of tissue using biocompatible materials and cells.
Collaborative Project (Largescale integrating project)
1.4 HEALTH-2009-1.4-3: Activation of endogenous cells as an approach to regenerative medicine.
Collaborative Project (Largescale integrating project)
2. TRANSLATING RESEARCH FOR HUMAN HEALTH
2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING
2.2.1. Brain and brain-related diseases
2.2.1. HEALTH-2009-2.2.1-1: Synaptopathies: genesis, mechanisms and therapy.
Collaborative Project (Largescale integrating project)
2.2.1. HEALTH-2009-2.2.1-2: Identifying genetic and environmental interactions in schizophrenia.
Collaborative Project (Largescale integrating project)
2.2.1. HEALTH-2009-2.2.1-3: Optimising current therapeutic approaches to schizophrenia.
Collaborative Project (Largescale integrating project)
FP7 Cooperation Work Programme: Health
2.2.1. HEALTH-2009-2.2.1-4: Understanding the blood brain barrier (BBB) to improve drug delivery to the brain.
Collaborative Project (Small or medium-scale focused research project)
2.2.1. HEALTH-2009-2.2.1-5: Psycho-social factors of brain disorders.
Coordination and Support Action (Coordinating Action)
2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH
2.3.1. Anti-microbial drug resistance including fungal pathogens
2.3.1 HEALTH-2009-2.3.1-1: Global collaborative research on the prevention of antibiotic resistance
Collaborative Project (Largescale integrating project)
2.3.1 HEALTH-2009-2.3.1-2: Impact of specific antibiotic therapies on the prevalence of resistant bacteria in the human
host.
Collaborative Project (Small or medium-scale focused research project)
2.3.1. HEALTH-2009-2.3.1-3: Clinical evaluation of point-of-care diagnostic tests for microbial detection and identification,
antibiotic susceptibility determination and biomarkers.
Collaborative Project (Small or medium-scale focused research project)
2.3.2. HIV/AIDS, malaria and tuberculosis
2.3.2. HEALTH-2009-2.3.2-1: Integration of European efforts in research on malaria.
Network of Excellence
2.3.2. HEALTH-2009-2.3.2-2: Identification and pre-clinical testing of new vaccine candidates for tuberculosis.
Collaborative Project (Largescale integrating project)
2.3.2. HEALTH-2009-2.3.2-3: Discovery and/or development of new and promising anti-HIV microbicides.
Collaborative Project (Largescale integrating project)
2.3.2. HEALTH-2009-2.3.2-4: Mucosal and topical vaccines for poverty-related diseases (HIV/AIDS, malaria and/or TB).
Collaborative Project (Largescale integrating project)
2.3.2. HEALTH-2009-2.3.2-5: Translational vaccine research for poverty-related diseases (HIV/AIDS, malaria and/or TB).
Collaborative Project (Small or medium-scale focused research project)
2.3.3. Potentially new and re-emerging epidemics
2.3.3. HEALTH-2009-2.3.3-1: Efficacy and effectiveness of personal protection equipment and other measures against
influenza transmission.
Collaborative Project (Small or medium-scale focused research project)
2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES
2.4.2. Cardiovascular diseases
2.4.2. HEALTH-2009-2.4.2-1: Improved or new therapeutic approaches for the treatment of heart failure.
Collaborative Project (Largescale integrating project)
2.4.2. HEALTH-2009-2.4.2-2: Cardiac arrhythmias: from genes to improved management of patients.
Collaborative Project (Largescale integrating project)
2.4.2. HEALTH-2009-2.4.2-3: Translation of basic knowledge on inherited cardiomyopathies into clinical practice.
Collaborative Project (Small or medium-scale focused research project)
2.4.3. Diabetes and obesity
2.4.3. HEALTH-2009-2.4.3-1: Novel therapeutical approach to pregnancy-induced diabetes.
Collaborative Project (Small or medium-scale focused research project)
2.4.3. HEALTH-2009-2.4.3-2: Novel immunotherapies for type 1 diabetes.
Collaborative Project (Largescale integrating project)
2.4.3. HEALTH-2009-2.4.3-3: Molecular pathways in food intake at CNS-liver-gut regulation level.
Collaborative Project (Small or medium-scale focused research project)
2.4.4. Rare diseases
2.4.4. HEALTH-2009-2.4.4-1: Rare neurological diseases. Collaborative Project (Small or medium-scale focused
research project)
2.4.4. HEALTH-2009-2.4.4-2: Preclinical development of substances with a clear potential as orphan drugs.
Collaborative Project (Small or medium-scale focused research project)
2.4.5. Other chronic diseases
2.4.5. HEALTH-2009-2.4.5-1: Prevention and treatment of nonalcoholic fatty liver disease (NAFLD).
Collaborative Project (Small or medium-scale focused research project)
2.4.5. HEALTH-2009-2.4.5-2: Cellular and molecular mechanisms of the development of chronic kidney disease (CKD).
Collaborative Project (Largescale integrating project)
3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS
3.1. TRANSLATING THE RESULTS OF CLINICAL RESEARCH OUTCOME INTO CLINICAL PRACTICE INCLUDING BETTER USE OF MEDICINES, AND APPROPRIATE USE OF BEHAVIOURAL AND
ORGANISATIONAL INTERVENTIONS AND NEW HEALTH THERAPIES AND TECHNOLOGIES
3.1. HEALTH-2009-3.1-1: Patient Safety: Effective implementation of prevention strategies for healthcare associated infections.
Collaborative Project (Small or medium-scale focused research project)
3.1. HEALTH-2009-3.1-2: Improve quality and safety of hospital care.
Collaborative Project (Small or medium-scale focused research project)
3.1. HEALTH-2009-3.1-3: Complementary and Alternative Medicine.
Coordination and Support Action (Coordinating Action)
3.1. HEALTH-2009-3.1-4: Improved treatment of chronic diseases in developing countries.
Collaborative Project (Small or medium-scale focused research project)
3.2. QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS
3.2. HEALTH-2009-3.2-1: Organisation of dementia care. Collaborative Project (Small or medium-scale focused research project)
3.2. HEALTH-2009-3.2-2: Healthcare outcomes and cost-benefits. Collaborative Project (Small or medium-scale focused research project)
3.2. HEALTH-2009-3.2-3: Primary care quality linkage to costs. Collaborative Project (Small or medium-scale focused research project)
3.2. HEALTH-2009-3.2-4: Impact of cross border collaboration on health services.
Collaborative Project (Small or medium-scale focused research project)
3.2. HEALTH-2009-3.2-5: Research access to comparable healthcare data.
Coordination and Support Action (Coordinating Action)
3.2. HEALTH-2009-3.2-6: Scoping study to address the methodological challenges of quantifying the socio-economic
burden of brain diseases in the enlarged European Union compared to other major diseases.
Coordination and Support Action (Supporting Action)
3.3. ENHANCED HEALTH PROMOTION AND DISEASE PREVENTION
3.3. HEALTH-2009-3.3-1: Child and adolescent mental health. Collaborative Project (Small or medium-scale focused
research project)
3.3. HEALTH-2009-3.3-2: Environmental prevention of substance abuse by adolescents.
Collaborative Project (Small or medium-scale focused research project)
3.3. HEALTH-2009-3.3-3: Ageing cohorts. Collaborative Project (Largescale integrating project)
3.3. HEALTH-2009-3.3-4: Birth/Mother - Child Cohorts coordination Coordination and Support
Action (Coordinating Action)
3.3. HEALTH-2009-3.3-5: European child health research platform
Coordination and Support Action (Coordinating Action)
4. OTHER ACTIONS ACROSS THE HEALTH THEME
4.1. COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME
4.1. HEALTH-2009-4.1-1: Monitoring tool and technology transfer analysis for health grants during FP7.
Coordination and Support Action (Supporting Action)
4.1. HEALTH-2009-4.1-2: Dissemination of results from research
in Life Sciences and Biotechnology for Health to the general public and/or information multipliers.
Coordination and Support Action (Coordinating or Supporting Action)
4.1. HEALTH-2009-4.1-3: Targeting publication bias. Coordination and Support Action (Supporting Action)
4.2. RESPONDING TO EU POLICY NEEDS
4.2. HEALTH-2009-4.2-1: Adapting off-patent medicines to the specific needs of paediatric populations.
Collaborative Project (Small or medium-scale focused research project)
4.2. HEALTH-2009-4.2-2: Study of the Arrhythmogenic potential of different classes of medicines.
Collaborative project (Small or medium-scale focused research project).
4.2. HEALTH-2009-4.2-3: Human Papillomavirus Vaccination (HPV) and cervical cancer screening programmes: estimate of
impact of different policy options by way of disease modelling and health economics.
Collaborative Project (Small or medium-scale focused research project)
4.2. HEALTH-2009-4.2-4: Coordinating action on organ procurement and transplantation with a focus on new EU Member States.
Coordination and Support action (Coordinating action)
4.3. SPECIFIC INTERNATIONAL COOPERATION ACTIONS (SICA)
4.3.1. Neglected infectious diseases.
4.3.1. HEALTH-2009-4.3.1-1: Discovery and development of new vaccines or drugs for helminth infections (SICA).
Collaborative Project (Small or medium-scale focused research project)
4.3.1. HEALTH-2009-4.3.1-2: Identification and development of vaccine candidates for neglected bacterial infections (SICA).
Collaborative Project (Small or medium-scale focused research project)
4.3.1. HEALTH-2009-4.3.1-3: Human immune responses to coinfections of poverty-Related (HIV, malaria, TB) and neglected infectious diseases (SICA).
Collaborative Project (Largescale integrating project)
4.3.2. International Public Health and Health Systems
4.3.2. HEALTH-2009-4.3.2-1: Strategies and interventions for improving reproductive health (SICA).
Collaborative Project (Small or medium-scale focused research project)
4.3.2. HEALTH-2009-4.3.2-2: Access to medicines (SICA). Collaborative Project (Small or medium-scale focused research project)
4.3.2. HEALTH-2009-4.3.2-3: Integration of Disease Surveillance and Health Systems Response (SICA).
Collaborative Project (Small or medium-scale focused research project)
4.3.3. Coordinated topics with Russia
4.3.3. HEALTH-2009-4.3.3-1 (SICA): Comparative population genetic studies on multifactorial diseases.
Collaborative Project (Small or medium-scale focused research project)
4.3.3. HEALTH-2009-4.3.3-2: Mechanisms of diabetic and weightrelated co-morbidity in heart failure (SICA).
Collaborative Project (Small or medium-scale focused research project)
Indicative budget breakdown Call FP7-HEALTH-2009-single-stage
ACTIVITY/AREA Indicative budget28 (EUR million)
1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH
1.2 DETECTION, DIAGNOSIS AND MONITORING
1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS 120
2. TRANSLATING RESEARCH FOR HUMAN HEALTH
2.2 RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING 41
2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH 75
2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES 95
3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS
3.1. TRANSLATING THE RESULTS OF CLINICAL RESEARCH OUTCOME INTO CLINICAL PRACTICE INCLUDING BETTER USE OF MEDICINES, AND APPROPRIATE USE OF BEHAVIOURAL AND ORGANISATIONAL INTERVENTIONS AND NEW HEALTH
THERAPIES AND TECHNOLOGIES
3.2. QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS
3.3. ENHANCED HEALTH PROMOTION AND DISEASE PREVENTION 64
4. OTHER ACTIONS ACROSS THE HEALTH THEME
4.1. COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME 3
4.2. RESPONDING TO EU POLICY NEEDS 33
4.3.1. Neglected infectious diseases 27
4.3.2. International Public Health and Health Systems 12
4.3. SPECIFIC INTERNATIONAL COOPERATION ACTIONS (SICA)
4.3.3. Coordinated topics with Russia 6
Topics for two-stage submission and evaluation; deadline 1st stage 3 December 2008:
− HEALTH-2009-1.1-1: Computational tools for genome annotation and
genotype/phenotype data integration. FP7-HEALTH-2009-two-stage. The
projects should develop new computational tools and methods for
genome/proteome annotation to catalyse the progress of systems biology by
describing, for example, molecular interactions, pathways and networks. The
projects should enable the integration of the vast amount of data generated on gene
function with a human genome browser to facilitate complex data search in
systems biology approaches. Funding scheme: Collaborative Project (Large scale
integrating project). One or more proposals are expected to be funded.
− HEALTH-2009-1.1-2: High throughput tools and technologies to analyse
samples in large-scale human biobanks. FP7-HEALTH-2009-two-stage. The
multidisciplinary projects should improve existing and/or develop and test new
tools and technologies for phenotypic analysis of large numbers of human
biological samples. The projects may also include enhancing and optimisation of
the quality of the sample preservation technologies. This integrated set of tools and
technologies should be able to deliver high quality and reproducible data for
FP7 Cooperation Work Programme: Health
standardised large-scale data gathering and high throughput functional genomics
research in human biobanks. Funding scheme: Collaborative Project (Large scale
integrating project). One or more proposals are expected to be funded.
− HEALTH-2009-1.1-3: Tools, technologies and resources for the
characterisation of protein functions. FP7-HEALTH-2009-two-stage. The
projects should aim at generating a large resource of molecules that bind to
proteins in order to characterise the proteome and/or developing innovative tools
and technologies that facilitate structure/function characterisation of protein
complexes. Open-access to the resources generated within the project should be
encouraged. Funding scheme: Collaborative Project (Large scale integrating
project). One or more proposals are expected to be funded.
Topics for single-stage submission and evaluation; deadline 3 December 2008:
- HEALTH-2009-1.2-1: Development of tools for sensitive and specific in vitro
detection of proteins and their interactions for diagnostic, prognostic and
monitoring purposes. FP7-HEALTH-2009-single-stage. The focus should be to
develop tools and reagents for the identification of alterations of protein
expression patterns, as well as modifications of and interactions among proteins in
disease processes for early specific diagnosis, prognosis or monitoring.
Deliverables should be innovative and improved molecular procedures, required to
achieve the necessary sensitivity and specificity and to distinguish close variants.
The procedures should be able to identify and quantify soluble proteins in body
fluids and/or to image their distribution in cells and tissues, preferably for parallel
analysis. Active participation of industry, especially SMEs, could lead to an
increased impact of the research proposed, and this will be considered in the
evaluation of the proposal. Funding scheme: Collaborative Project (Small or
medium-scale focused research project).
FP7 Cooperation Work Programme: Health
- HEALTH-2009-1.2-2: Design of methods suited to identify epigenetic factors
and their use in the genetic diagnosis of relevant disorders. FP7-HEALTH-
2009-single-stage. The focus should be to develop novel strategies to determine
the epigenetic profile of genes known to be subject to specific epigenetic processes
(for example: imprinting or effect of microRNAs). Deliverables should be new
diagnostic tests for epigenetic modifications in disorders where several genes and
environment factors can contribute to causation. Funding scheme: Collaborative
Project (Small or medium-scale focused research project).
- HEALTH-2009-1.2-3: Novel MR-compatible PET detectors for simultaneous
PET/MRI imaging. FP7-HEALTH-2009-single-stage. The focus should be to
develop novel magnetic-field-compatible nuclear detectors for PET imaging,
aimed at maximizing the benefits of simultaneous PET/MRI acquisition, which
can also be used efficiently and implemented in stand alone PET or SPECT
applications. These detectors should operate in high magnetic fields, as used in
MRI, without performance degradation, and have high spatial and time resolution.
A dedicated integrated readout of high quality should also be developed. The full
detector should be compact so as to allow good integration with an MRI system.
Globally, it should allow fully exploiting the advantages of both PET and MR
technologies in a simultaneous imaging modality and for implementation in both
preclinical and clinical/human PET stand-alone systems beyond the state-of-theart.
Active participation of industry, especially SMEs, could lead to an increased
impact of the research proposed, and this will be considered in the evaluation of
the proposal. Funding scheme: Collaborative Project (Large scale integrating
project).
- HEALTH-2009-1.2-4: Novel imaging systems for in vivo monitoring and
quality control during tumour ion beam therapy. FP7-HEALTH-2009-singlestage.
The focus should be to develop novel imaging instruments, methods and
tools for monitoring, in vivo and preferably in real time, the 3-dimensional
distribution of the radiation dose effectively delivered within the patient during ion
beam therapy of cancer. The ions should be protons or heavier ions. The system
should typically be able to quantify the radiation dose delivered, to determine the
agreement between the planned target volume and the actually irradiated volume,
and for decreasing localisation uncertainties between planned and effective
positions (e.g. of tissues or organs), and between planned and effective dose
distribution during irradiation. It should aim at improving quality assurance,
increasing target site (tumour) to normal tissue dose ratio and better sparing
normal tissue. Funding scheme: Collaborative Project (Small or medium-scale
focused research project).
- HEALTH-2009-1.2-5: Activatable or smart in vivo imaging agents reporting
on physico-chemical or molecular changes relevant to the diagnosis and/or
monitoring of diseases (in coordination with NMP theme). FP7-HEALTH-
2009-single-stage. The focus should be to develop imaging agent(s) for the
detection and/or monitoring of disease processes, that can be externally activated
in vivo or react to disease-associated variations in the body. The variations can be
endogenous disease-associated conditions such as special enzymes, pH or pO2
changes, or other. In the case of external activation, it could be realised by
applying radiofrequency, ultrasound, heat, light or magnetic fields. The proposed
concept should be pre-clinically tested and potentially suited for later clinical
FP7 Cooperation Work Programme: Health
Page 12 of 62
application. Active participation of industry, especially SMEs, could lead to an
increased impact of the research proposed, and this will be considered in the
evaluation of the proposal. Funding scheme: Collaborative Project (Small or
medium-scale focused research project).
- HEALTH-2009-1.2-6: Evaluation of the potential health impact of diagnostic
imaging agents doses. FP7-HEALTH-2009-single-stage. The focus should be to
summarise and evaluate current knowledge on the impact on patients’ health of
small and non- or little-repetitive doses (amounts) of radioactive, biological and/or
chemical substances, as currently used in diagnostic imaging procedures. Results
should be reported and enable the development of recommendations and
guidelines to drive scientific and technologic innovation to improve patient
healthcare in medical imaging. If the study concludes that a clinical study is
needed, it should detail it. People involved in legislative approval of these agents
for human use should at least be consulted and, if possible, involved. A given
proposal should focus on either radioactive or non-radioactive imaging agents.
Projects should not exceed 18 months. A maximum of one project will be
supported for each of these 2 areas. Funding scheme: Coordination and Support
Action (Supporting Action).
1.3 Suitability, safety, efficacy of therapies
Alternative testing strategies
The objective is to develop and implement a co-ordinated approach towards the faster
application of existing research results for safety testing in industry and for regulatory
purposes, fully respecting existing legislation on animal protection. The pharmaceutical
industry and several other industrial sectors largely depend upon animal studies for
predicting human toxicity and efficacy of their products. In addition, several industrial
sectors are already obliged to apply available methods to replace, reduce and refine animal
use (3Rs) in safety evaluations. Therefore, faster progress in academic research needs to be
matched with the faster uptake of alternative approaches in industry and regulation in order
to significantly reduce the use of animal tests.
Expected impact: Bringing the specific know-how, valuable technologies, ideas and
expertise developed by academic research in this field to the outside world will result in an
optimised use of knowledge and know how and will significantly help to implement the
Replace, Reduce and Refine strategy (3Rs). In this way all promising new technologies
will be taken into consideration. The gap between university research and industrial
demand will be closed and new synergies and interaction formats between industry and
academia will be created in the field of the 3Rs.
Topic for 3rd call, single-stage submission and evaluation; deadline 3 December 2008:
- HEALTH-2009-1.3-1: New initiatives towards the implementation of the
Replace, Reduce and Refine strategy. FP7-HEALTH-2009-single-stage. The
development of new ‘3R’-methods as modern alternative approaches to safety
testing requires a better co-ordination of the various activities involved. This
FP7 Cooperation Work Programme: Health
should start with the mapping of existing research results, followed by the
development of new ideas for alternative approaches and strategies, and promotion
of communication, education, validation and acceptance of alternative approaches.
The funding scheme would be a support and co-ordination action aimed at
bringing academic research in a pro-active way closer to the industrial landscape
in order to effectively develop concrete collaboration projects with industrial
partners. This coordination action should build particularly on the success of
activities carried out in the EU RTD Framework Programmes and in national
activities. Funding scheme: Coordination and Support Action (Coordinating
Action).
WEKOMS 
